GSKs Gepotidacin Could Become First Novel Antibiotic For uUTIs In 20 Years
Following Pivotal Success
The UK major’s first-in-class asset has matched standard-of-care in two Phase III urinary tract infection trials, setting it up to become the first novel antibiotic for the condition in 20 years with a clear niche in the second-line setting.
